1338326-92-3

Upstream product

• 1338326-93-4 4-bromo-3-chlorobenzyl methanesulfonate 
• 5188-07-8 sodium thiomethoxide 
• 120077-68-1 (4-bromo-3-chlorophenyl)methanol 
• 68120-44-5 1-bromo-4-(bromomethyl)-2-chloro-benzene 

Downstream Products

• 1338327-32-4 2-(2-chloro-4-(methylthiomethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1338326-91-2 1-bromo-2-chloro-4-(methylsulfonylmethyl)benzene 
• 1338326-42-3 4-amino-6-(2'-chloro-4'-(methylsulfonylmethyl)biphenyl-4-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338326-90-1 2-(2-chloro-4-(methylsulfonylmethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1338326-70-7 (R)-4-amino-6-(2'-chloro-4'-(methylsulfonylmethyl)biphenyl-4-yl)-8-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338327-31-3 (R)-4-amino-6-(2'-chloro-4'-(methylthiomethyl)biphenyl-4-yl)-8-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 

Relevant academic research and scientific papers

ANTIPROLIFERATION COMPOUNDS AND USES THEREOF

The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.